![Country [Change]](http://images.sciex.com/shared/icons/globe-white.png){kind=icon}
Country [Change] 
Shop
Partners
Bringing a new drug to market is a costly and complex process. With potentially hundreds of thousands of new compounds to screen during drug discovery, sample throughput is a common bottleneck for pharmaceutical companies. So how do you overcome this barrier?
Tags
Want to accelerate your drug discovery workflow?
Bringing a new drug to market is a costly and complex process. With potentially hundreds of thousands of new compounds to screen during drug discovery, sample throughput is a common bottleneck for pharmaceutical companies. So how do you overcome this barrier?
Easing the demands of a compliant pharmaceutical laboratory
At SCIEX, we are proud to provide analytical systems to the pharmaceutical industry. We work hard to understand the demands of analytical work and the processes required to develop and manufacture drugs.
What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)
SCIEX was very proud to have an illustration of the Acoustic Ejection Mass Spectrometry (AEMS) technology that powers the Echo® MS system on the front cover of the Journal of the American Society for Mass Spectrometry in January 2023. The associated article—Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry—was co-authored by scientists from SCIEX and Merck.
5 Reasons to choose the Echo® MS system for high-throughput drug discovery
Have you thought about introducing new technology into your high-throughput drug discovery lab? Here are 5 reasons the Echo® MS system could make a difference for you.
What have we learned from the nitrosamine crisis?
The pharmaceutical industry is facing an ongoing issue with genotoxic impurities (GTIs). Over the past year, we have witnessed genotoxic impurities affect several drugs, including those used to treat elevated blood pressure, heartburn and acid reflux. Angiotensin II...
Top 7 Echo® MS system customer questions—answered
You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to...
An interview from the Science Explorer about the Echo® MS system
The Science Explorer interviews Neil Walsh from SCIEX to discuss the significant application areas of the Echo® MS System and what makes this system so attractive to biopharmaceutical laboratories.
Developing a method for nitrosamine analysis in pharmaceutical products
In our previous blogs we discussed the need for a more comprehensive approach for monitoring contaminants in finished drug products.1,2 Here we cover a generalized approach for the targeted, quantitative LC-MS/MS analysis of several commonly encountered nitrosamines in pharmaceuticals and ways to address specific challenges with their analysis.
The Echo® MS system: Is it reproducible? Yes… yes… yes!
The Echo® MS System is an exciting new platform that dramatically speeds sample analysis for quantitative MS studies. Because of its unique and innovative technology, the system can analyze samples faster than ever before—but without the need for LC.
Scale it up! The Echo® MS System delivers unprecedented levels of productivity
Imagine the productivity gains your lab could achieve with a technology that not only analyzes samples up to 50x faster than conventional quantitative LC-MS, but also eliminates tedious sample preparation, time-consuming LC method development and chromatographic run...
How fast is fast? The Echo® MS System sets the record
How fast is fast? Cheetahs. Usain Bolt. Tachyons. The Echo® MS system. What do these things have in common? They’re all fast. REALLY fast. In fact, they’re the fastest in their categories: the fastest land mammal, the fastest human sprinter, the fastest subatomic...
A new generation of therapeutic modalities
There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000...
Are we proactively solving the nitrosamine crisis?
In my previous blog, I spoke about the FDA recall of angiotensin II receptor blockers like losartan. This recall was due to the presence of genotoxic nitrosamines. Is a proactive approach the way to mitigate risk? Recently, the FDA has re-issued the 2018 guidance to...
Full, partial and empty capsid ratios for AAV analysis: What’s the big deal?
For many of you working to develop gene therapy drugs, you know that the time to market the drug is critical. Because gene therapeutics cure diseases by targeting specific genes, it is a constant race to see who develops the drug first. Unlike other classes of drugs where multiple medications can be used to treat a disease, whoever is first to develop a gene therapy drug wins.
Microflow for metabolite ID: a win all around
Over the last several years there has been a slow and steady progression within the LC-MS community to move traditional high-flow applications to lower flow rates. In particular, moving into the microflow regime has proven to be a simple adjustment in methodology that...
Ever thought of breaking the high-throughput sound barrier for drug discovery?
Wouldn’t it be great if we really could “get time back” or even “buy time”? When developing pharmaceuticals, it takes years to bring a new therapy to the market due to the linear nature of the process. As the saying goes, “Time waits for no one.” But what if we could...
Why Conventional Flow LC-MS/MS Bioanalysis Is out and Microflow Is In
New technologies can transform a laboratory’s throughput and efficiency. At Alturas, if we try out a new technology, we ask: Does it work? Is it convenient? Is it rugged? Are we getting good results? When we look at the convenience, uptime, and overall data that we’re...
Metabolism and Biotransformation – What Are You Missing?
Are you looking to improve your MetID studies? Want to achieve the productivity and throughput you need to keep your projects moving and have complete confidence that you’re not missing any low level or parent-like metabolites in your sample? In this blog, we’re...
Calling all Bioanalysts: We’re Making Bioanalytical Selectivity Challenges History
High selectivity is a key component of successful quantitative bioanalysis. As a bioanalyst, we need consistently accurate and robust quantitation of small molecule therapeutics and metabolites. Challenged by complicated matrix interferences, high baseline signal, and...
Enhancing In Vitro ADME Screening
LC-MS technology is helping contract research organization Cyprotex Discovery Ltd. perform bioanalysis of small molecules, peptides, and other pharmaceuticals, enabling quantification to be performed in complex matrices during in vitro ADME studies.
A Fleet of Analyzers Keeps Work Flowing
An Interview with Timothy Sangster, Head of Bioanalysis and Immunology, Charles River Laboratories, Edinburgh
Do You Want to Accelerate Quantitative Assays for Antibody Drug Conjugates?
Are you tasked with the bioanalysis of antibody drug conjugates (ADCs)? If so, you know they represent a rapidly growing class of biotherapeutics, but their unique chemical structure makes quantitative analysis particularly challenging.
The Only Solution You Need for Fast MetID
If you work in the breakneck world of therapeutic development, then you probably don’t even have time to read this blog (but we thought we would write it anyways, just in case). Drug metabolism samples are coming into your lab fast and furious. You need to turn them around in hours so that chemists and biologists can optimize the effectiveness of the therapeutic candidate. Time for lunch? We don’t think so!
The Application of Research Grade MetabolitePilot™ Software for the Determination of the Catabolic Peptide Products of Exenatide
The stability of peptide and protein biotherapeutics directly impacts their pharmacokinetic profile, efficacy, and safety. It is therefore essential to characterize the stability of a given bio-therapeutic including both in-vivo and in-vitro catabolism, thereby...
Superbugs, Antibiotic Resistance, and the QTRAP® 6500+ System
‘Superbugs’, or bacteria that have developed antibiotic resistance as a result of adapting to the drugs used in their treatment, are dangerous infections that doctors struggle to stop from spreading. Even common infections such as urinary tract infections and...
Drug Metabolism and Bioanalysis Journal Articles Focus on Drug Metabolism and so Much More
Check-out the top articles that focus on innovations in drug metabolism as well as small molecule quantitation and biologics bioanalysis. Exciting advancements! We can’t wait to see all that will come in 2016! Quantitative analysis of maytansinoid (DM1) in human serum...
Contact Support